Docket

40556

His Majesty the King in Right of the Province of British Columbia v. Apotex Inc., Apotex Pharmaceutical Holdings, Inc., et al.

(British Columbia) (Civil) (By Leave)

Judgments on applications for leave to appeal are rendered by the Court, but are not necessarily unanimous.

Proceedings
Date Proceeding Filed By
(if applicable)
2023-06-21 Close file on Leave
2023-05-25 Copy of formal judgment sent to Registrar of the Court of Appeal and all parties
2023-05-25 Judgment on leave sent to the parties
2023-05-25 Judgment of the Court on the application for leave to cross-appeal, The applications for leave to cross-appeal are dismissed with costs to the applicant.


Côté and Rowe JJ. took no part in the judgment.

Dismissed
2023-05-25 Judgment of the Court on the application for leave to appeal, The application for leave to appeal from the judgments of the Court of Appeal for British Columbia (Vancouver), Numbers CA48049, CA48050, CA48051, CA48052 CA48053, CA48054, CA48055, CA48056, CA48057, CA48058, CA48060, CA48062, and CA48067, 2022 BCCA 366, dated November 2, 2022, is dismissed with costs to the respondents, Apotex Inc., Bristol-Myers Squibb Canada, Bristol-Myers Squibb Company, Mylan Pharmaceutical ULC, Janssen Inc., Sandoz Canada Inc., Teva Canada Limited, Teva Canada Innovation G.P. – S.E.N.C., Actavis Pharma Company, Ranbaxy Pharmaceuticals Canada Inc., Pharmascience Inc., Imperial Distributors Canada Inc., LPG Inventory Solutions, McKesson Canada Corporation, Noramco Inc., Sanis Health Inc., Shoppers Drug Mart Inc., Valeant Canada LP / Valeant Canada S.E.C., Bausch Health Companies Inc., Paladin Labs, Endo Pharmaceuticals Inc., Endo International PLC and Endo Ventures Ltd.

The applications for leave to cross-appeal are dismissed with costs to the applicant.


Côté and Rowe JJ. took no part in the judgment.
Dismissed, with costs
2023-04-17 All material on the application for leave to cross-appeal submitted to the Judges, for consideration by the Court
2023-04-17 All materials on application for leave submitted to the Judges, for consideration by the Court
2023-04-03 Reply to the memorandum in response to the argument on cross-appeal, (Book Form), Completed on: 2023-04-04, (Printed version filed on 2023-04-11) Teva Canada Limited, Teva Canada Innovation G.P. – S.E.N.C., Actavis Pharma Company, Ranbaxy Pharmaceuticals Canada Inc., Pharmascience Inc.
2023-04-03 Reply to the memorandum in response to the argument on cross-appeal, (Book Form), Completed on: 2023-04-04, (Printed version filed on 2023-04-04) Mylan Pharmaceutical ULC
2023-03-29 Correspondence received from, Supplemental reasons on costs in this proceeding His Majesty the King in Right of the Province of British Columbia
2023-03-22 Book of authorities, (Book Form), Completed on: 2023-03-27, (Printed version filed on 2023-03-23) His Majesty the King in Right of the Province of British Columbia
2023-03-22 Applicant's reply to respondent's argument, (Book Form), (Included in the memorandum of argument in response to the cross-appeal), Completed on: 2023-03-27, (Printed version filed on 2023-03-23) His Majesty the King in Right of the Province of British Columbia
2023-03-22 Memorandum of argument in response to the cross-appeal, (Book Form), (Included in the applicant's reply to respondent's argument), Completed on: 2023-03-27, (Printed version due on 2023-03-29) His Majesty the King in Right of the Province of British Columbia
2023-02-17 Notice of name, (Letter Form), (Printed version filed on 2023-02-17) Bristol-Myers Squibb Canada, Bristol-Myers Squibb Company
2023-02-17 Certificate (on limitations to public access), (Letter Form), (Printed version filed on 2023-02-17) Bristol-Myers Squibb Canada, Bristol-Myers Squibb Company
2023-02-17 Application for leave to cross-appeal, (Book Form), Completed on: 2023-04-04, (Printed version filed on 2023-02-17) Bristol-Myers Squibb Canada, Bristol-Myers Squibb Company
2023-02-17 Respondent's response on the application for leave to appeal, (Book Form), Completed on: 2023-04-04, (Printed version filed on 2023-02-17) Bristol-Myers Squibb Canada, Bristol-Myers Squibb Company
2023-02-17 Notice of name Janssen Inc., Johnson & Johnson
2023-02-17 Certificate (on limitations to public access) Janssen Inc., Johnson & Johnson
2023-02-17 Respondent's response on the application for leave to appeal, (Book Form), Completed on: 2023-02-26 Janssen Inc., Johnson & Johnson
2023-02-17 Application for leave to cross-appeal, (Book Form), Completed on: 2023-02-26, (Printed version filed on 2023-02-24) Janssen Inc., Johnson & Johnson
2023-02-17 Notice of name Mylan Pharmaceutical ULC
2023-02-17 Certificate (on limitations to public access) Mylan Pharmaceutical ULC
2023-02-17 Application for leave to cross-appeal, (Book Form), Completed on: 2023-02-27, (Printed version due on 2023-02-24) Bristol-Myers Squibb Canada, Bristol-Myers Squibb Company
2023-02-17 Respondent's response on the application for leave to appeal, (Book Form), Completed on: 2023-02-26, (Printed version filed on 2023-02-17) Mylan Pharmaceutical ULC
2023-01-19 Letter acknowledging receipt of an incomplete application for leave to appeal and without formal Court of Appeal order, FILE OPENED 2023-01-19
2023-01-03 Certificate (on limitations to public access), (Letter Form), 23A, (Printed version due on 2023-01-10) His Majesty the King in Right of the Province of British Columbia
2023-01-03 Book of authorities, (Book Form), Completed on: 2023-01-19, (Printed version filed on 2023-01-10) His Majesty the King in Right of the Province of British Columbia
2023-01-03 Application for leave to appeal, (Book Form), (2 volumes), Required:
CA Order (Court Order Form rec'd 2023-01-19 - Estimate as to when court order will be filed 2023-04-19), Completed on: 2023-04-18, (Printed version filed on 2023-01-10)
His Majesty the King in Right of the Province of British Columbia
 

loading